Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 12;9(6):1796-1812.
doi: 10.1016/j.stemcr.2017.10.020. Epub 2017 Nov 22.

Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells

Jieming Zeng  1 , Shin Yi Tang  2 , Lai Ling Toh  3 , Shu Wang  4
Affiliations

Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells

Jieming Zeng et al. Stem Cell Reports. .

Abstract

Current donor cell-dependent strategies can only produce limited "made-to-order" therapeutic natural killer (NK) cells for limited patients. To provide unlimited "off-the-shelf" NK cells that serve many recipients, we designed and demonstrated a holistic manufacturing scheme to mass-produce NK cells from induced pluripotent stem cells (iPSCs). Starting with a highly accessible human cell source, peripheral blood cells (PBCs), we derived a good manufacturing practice-compatible iPSC source, PBC-derived iPSCs (PBC-iPSCs) for this purpose. Through our original protocol that excludes CD34+ cell enrichment and spin embryoid body formation, high-purity functional and expandable NK cells were generated from PBC-iPSCs. Above all, most of these NK cells expressed no killer cell immunoglobulin-like receptors (KIRs), which renders them unrestricted by recipients' human leukocyte antigen genotypes. Hence, we have established a practical "from blood cell to stem cells and back with less (less KIRs)" strategy to generate abundant "universal" NK cells from PBC-iPSCs for a wide range of patients.

Keywords: cancer; cell therapy; cytotoxicity; immunotherapy; induced pluripotent stem cells; killer cell immunoglobulin-like receptors; natural killer cells; peripheral blood cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Generation of NK Cells from hPSCs (A) A schematic of a two-stage protocol for production of NK cells from hPSCs. (B–I) Morphological changes during differentiation of H1 cells into NK cells. Phase contrast images show (B) undifferentiated H1 cells; (C) H1 and OP9 co-culture, day 12; (D) first differentiated cells and OP9-DLL1 co-culture, day 7 (day 19); (E) second differentiated cells and OP9-DLL1 co-culture, day 7 (day 26); (F and G) third differentiated cells and OP9-DLL1 co-culture, day 7 (day 33); (H and I) fourth differentiated cells and OP9-DLL1 co-culture, day 7 (day 40). (J–L) Phenotypic changes during differentiation of H1 cells into NK cells. Flow cytometric analysis shows (J) CD34+ cells from H1 and OP9 co-culture, day 12; (K and L) CD56+ CD45+ cells from third (day 33) and fourth (day 40) co-culture on OP9-DLL1.
Figure 2
Figure 2
Generation of PBC-iPSCs for Production of NK Cells PBCs from different donors were used to generate various PBC-iPSC lines. Results were obtained using PBC-iPSC (donor A) lines (A–K) and PBC1-iPSC (donor B) lines (L). (A) Morphology of two PBC-iPSC (donor A) lines, PBC-iPSC#9 and PBC-iPSC#8.3. (B and C) TCRB gene (B) and TCRG gene (C) clonality assays to detect rearranged TCRβ and TCRγ chain genes in PBC-iPSC (donor A) lines. Positive amplified product is indicated by the yellow arrow. (D–K) Production of NK cells from two PBC-iPSC (donor A) lines, PBC-iPSC#9 and PBC-iPSC#8.3. (D–G) Phenotypic changes during differentiation of non-T cell-derived PBC-iPSC#9 line into NK cells. Flow cytometric analysis shows no TCRαβ expression during differentiation. (H–K) Phenotypic changes during differentiation of T cell-derived PBC-iPSC#8.3 line into NK cells. Flow cytometric analysis shows re-expression of TCRαβ during differentiation. (L) TCRB gene and TCRG gene clonality assays to detect rearranged TCRβ and TCRγ chain genes in PBC1-iPSC (donor B) lines.
Figure 3
Figure 3
Morphology, Purity, and Phenotype of PBC-iPSC-NK Cells (A) Morphology of fifth differentiated cells and OP9-DLL1 co-culture, day 7 (day 47) starting with PBC-iPSC#9 (donor A). (B) Morphology of PBC-iPSC#9-NK cells (donor A) after harvesting and purification by density gradient centrifugation using Ficoll-Paque followed by overnight culture. (C) Purity of PBC-iPSC#9-NK cells (donor A) as evaluated by flow cytometry. (D) Phenotype of PBC-iPSC#9-NK cells (donor A). (E) Phenotype of PBC1-iPSC#4-NK cells (donor B).
Figure 4
Figure 4
Functions of PBC-iPSC-NK Cells (A and B) IFN-γ secretion by PBC-iPSC#9-NK cells (donor A) upon stimulation with K562 and Raji cells as detected by ELISPOT assay. ELISPOT images (A) and spot counting (mean ± SD, n = 3) (B) are shown. (C and D) GrB secretion by PBC-iPSC#9-NK cells upon stimulation with K562 cells as detected by ELISPOT assay. ELISPOT images (C) and spot counting (mean ± SD, n = 3) (D) are shown. (E and F) Cytotoxicity of PBC-iPSC#9-NK cells against K562 and Raji cells as measured by flow cytometry. A representative flow cytometric analysis (E) and a result summary (F) are shown. (G and H) ADCC of PBC-iPSC#9-NK cells against Raji cells in the presence of anti-CD20 humanized antibody as measured by flow cytometry. A representative flow cytometric analysis (G) and a result summary (H) are shown. These data are representative of three independent experiments.
Figure 5
Figure 5
Expansion of Fresh and Cryopreserved PBC-iPSC-NK Cells (A and B) Expansion of fresh PBC-iPSC#9-NK cells by K562-mbIL15-41BBL in G-Rex10 starting with different NK cell numbers. Absolute numbers of NK cells during a 14-day expansion (A) and fold changes after expansion (B) are shown. (C and D) Phenotype (C) and cytotoxicity against K562 (D) of fresh PBC-iPSC#9-NK cells after expansion as measured by flow cytometry. (E) Viability of expanded PBC-iPSC#9-NK cells after freeze/thaw procedure. (F) Expansion of cryopreserved PBC-iPSC#9-NK cells. (G) Cytotoxicity of cryopreserved PBC-iPSC#9-NK cells against K562 after expansion. These data are representative of three independent experiments.
Figure 6
Figure 6
Cytotoxicity of PBC-iPSC-NK Cells against Cancer Cells Three different sources of PBC-iPSC-NK cells, including PBC-iPSC#9-NK cells (donor A), PBC1-iPSC#4-NK cells (donor B), and PBC2-iPSC#12-NK cells (donor C), were used for cytotoxicity assay against a wide variety of cancer cell lines: K562 (A), SK-OV-3 (B), SW480 (C), HCT-8 (D), MCF7 (E), and SCC-25 (F). PB-NK cells expanded from three different donors (donor 1, donor 2, and donor 3) were used as controls. (G–I) A short-term cultured primary tumor cell line CRC7.4 was derived from a colorectal cancer sample and characterized by immunostaining (G–J) and flow cytometry (K). These primary tumor cells were then use as _target cells to evaluate the cytotoxicity of PBC-iPSC#9-NK cells (L). PB-NK cells expanded from three donors (donor 4, donor 5, and donor 6) were used as controls. Student's paired two-tailed t test was used to analyze the difference between the specific lysis of _target cells by PBC-iPSC-NK cells and that by PB-NK cells. The p values were calculated for each type of _target cell and a p value less than 0.05 was considered to be statistically significant. These data are representative of three independent experiments.
Figure 7
Figure 7
KIR Typing of PBC-iPSC-NK Cells (A–J) KIR genotyping and mRNA expression profiling. Electrophoresis of PCR products of genomic DNA shows KIR gene content and endogenous β-actin gene of a PB-NK donor (donor 4) (A) and three PBC donors for PBC-iPSC#9 (donor A) (C), PBC1-iPSC#4 (donor B) (G), and PBC2-iPSC#12 (donor C) (I). Electrophoresis of PCR products of cDNA shows mRNA expression of KIR genes and endogenous β-actin gene in PB-NK cells (B), PBC-iPSC#9 cells (D), PBC-iPSC#9-NK cells (E), post-expansion PBC-iPSC#9-NK cells (F), PBC1-iPSC#4-NK cells (H), and PBC2-iPSC#12-NK cells (J). (K–P) KIR phenotyping of different NK cells by flow cytometry.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Benson D.M., Jr., Caligiuri M.A. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol. Res. 2014;2:99–104. - PMC - PubMed
    1. Benson D.M., Jr., Hofmeister C.C., Padmanabhan S., Suvannasankha A., Jagannath S., Abonour R., Bakan C., Andre P., Efebera Y., Tiollier J. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120:4324–4333. - PMC - PubMed
    1. Benson D.M., Jr., Cohen A.D., Jagannath S., Munshi N.C., Spitzer G., Hofmeister C.C., Efebera Y.A., Andre P., Zerbib R., Caligiuri M.A. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res. 2015;21:4055–4061. - PMC - PubMed
    1. Colucci F., Caligiuri M.A., Di Santo J.P. What does it take to make a natural killer? Nat. Rev. Immunol. 2003;3:413–425. - PubMed
    1. De Obaldia M.E., Bhandoola A. Transcriptional regulation of innate and adaptive lymphocyte lineages. Annu. Rev. Immunol. 2015;33:607–642. - PubMed

Publication types

MeSH terms

  NODES
Note 8
Project 1
twitter 2